Home / Companies / News / Bharat Serums secures nod to test sepsis drug on Covid-19 patients

Bharat Serums secures nod to test sepsis drug on Covid-19 patients

Injectable drug is already available in the market; firm has no plans to work on vaccine candidate

Serum institute, coronavirus, vaccine, pharma, drugs

Premium

BSVL is currently not working on any Covid-19 vaccine candidate and does not have any plans to do so.

3 min read Last Updated : Jun 11 2020 | 7:15 PM IST

Joining the list of drugs repurposed for Covid-19, a sepsis drug from Bharat Serums and Vaccines (BSVL) is getting into Phase III clinical trials.

The Mumbai-based biopharmaceutical firm — backed by US private equity player Advent International — has got approval from the drug regulator to start trials on the injectable drug that it sells under the brand U-Tryp. BSVL is not working on any Covid-19 vaccine and has no plans to do so.

ALSO READ: How govt's late afterthoughts and claims have haunted oil and gas sector

Speaking to Business Standard, BSVL Managing Director and Chief

Topics : Coronavirus

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in